When was Kartos Therapeutics founded?

Kartos Therapeutics was founded in 2018.

Where is Kartos Therapeutics located?

Kartos Therapeutics is headquartered in Redwood City, United States.

How many employees does Kartos Therapeutics have?

As of Aug 31, 2026, the latest employee count at Kartos Therapeutics is 64.

Where does Kartos Therapeutics rank among its competitors?

Kartos Therapeutics ranks 591st amongst 3289 active competitors, of which 1119 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Kartos Therapeutics?

Kartos Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Kartos Therapeutics - 2026 Company Profile, Funding & Competitors

Kartos Therapeutics is an acquired company based in Redwood City (United States), founded in 2018. It operates as a Developer of therapeutics for the treatment of cancer. The company has 3289 active competitors, including 1119 funded and 775 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for the treatment of cancer. The lead candidate of the company is Navtemadlin (KRT-232) oral MDM2 inhibitor for the treatment of Myelofibrosis (MF), Polycythemia Vera (PV), Acute Myeloid Leukemia (AML), and Merkel Cell Carcinoma (MCC).

Key Metrics

Founded Year

2018

Location

Redwood City, United States

Stage

Acquired

Investors

Orbimed & 1 more

Ranked

591^st among 3289 active competitors

Employee Count

64 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2981 more

Exit Details

Acquired by Ipsen (Jun 29, 2026)

View Kartos Therapeutics' full profile

Kartos Therapeutics got acquired by Ipsen on Jun 29, 2026.

Click here to take a look at Kartos Therapeutics's acquisition in detail

Kartos Therapeutics is a funded company. Kartos Therapeutics has 2 institutional investors.

View details of Kartos Therapeutics's funding rounds and investors

Kartos Therapeutics' employee count trend

Kartos Therapeutics has 64 employees as of Aug 26. Here is Kartos Therapeutics's employee count trend over the years:

Employee count trend for Kartos Therapeutics

Uncover Kartos Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kartos Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Kartos Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
591st	Kartos Therapeutics 2018, Redwood City (United States), Acquired	Developer of therapeutics for the treatment of cancer	-	Orbimed, SR One	50/100